AtriCure

AtriCure, Inc. engages in the development, manufacture, and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in Mason, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AtriCure excels in 2022, eyes growth in cardiac surgery market

AtriCure's strong performance in 2022 sets the stage for continued growth and profitability.
Focus on technological advancements and clinical trials to drive future revenue growth.
Addressing challenges like slower adoption and macro pressures with strategic planning.
Positioned for success with a robust product portfolio and international growth prospects.

AtriCure reports robust Q1 earnings, eyes growth amid competition

AtriCure's Q1 2023 performance was strong, with revenue growth and a focus on profitability. Challenges include cash burn and potential competition in the cryoSPHERE market. The company's innovative approach and growth projections offer promising opportunities.

AtriCure posts robust Q2 results, eyes international growth opportunities

AtriCure's Q2 performance showcased strong revenue growth, margin improvement, and strategic acquisitions, positioning the company for continued success.
While challenges like ongoing investments and product optimization exist, opportunities in international markets, acquisitions, and cardiac surgery trends offer avenues for future growth.
The company's focus on clinical trials, long-term market opportunities, and maintaining a strong balance sheet underscores its commitment to innovation and sustainable growth.

AtriCure (ATRC) reports robust Q3 earnings, eyes growth opportunities

AtriCure's strong Q3 performance and positive outlook for full year 2023 demonstrate growth potential across key franchises. Challenges include market transitions impacting pain management growth and the need to adapt to evolving market dynamics. Opportunities lie in new product launches, clinical trials, and market expansion strategies.

AtriCure reports robust Q4 growth, eyes new products and market opportunities

AtriCure's strong financial performance in Q4 2023 and expectations of 15-17% revenue growth in 2024 showcase sustained momentum.
The company's focus on innovation, product adoption, and market opportunities positions it well for future expansion and impact.
Balancing challenges like product development and market dynamics with pricing strength and operational efficiency will be key for continued success.

AtriCure excels in Q1 2024, eyes global impact with innovations

AtriCure's strong start in 2024 driven by revenue and EBITDA growth.
Focus on innovation, clinical trials, and international expansion.
Challenges include product adoption and R&D investment balance.
Opportunities lie in market leadership, new product launches, and global trials.

AtriCure posts strong Q2 results, eyes EU expansion and trial completion

AtriCure's Q2 2024 performance reflects robust revenue growth and positive EBITDA, driven by key franchise expansions and clinical trials.
While facing challenges such as increased operating expenses and a loss per share, the company maintains a focus on innovation and growth opportunities.
Revised full-year guidance and strategic product launches position AtriCure for continued growth and market leadership in the medical device sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded in 1994 and is headquartered in Mason, OH.

MASON, Ohio--( BUSINESS WIRE )--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023.

AtriCure to Announce Fourth Quarter and Full Year 2022 Financial Results and Participate in 2023 BTIG Medical Technology Conference

MASON, Ohio--( BUSINESS WIRE )--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced preliminary financial results for the fourth quarter and full year 2022 and provided 2023 financial guidance.

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2022, Provides Financial Outlook for 2023

A reasonable period of top-line growth across the core portfolio last quarter, coupled with strong guidance for FY22. Despite this, operating losses continue to widen, and NOPAT is thin even when capitalizing on R&D.

AtriCure: Despite Reasonable Top-Line Growth, No Change To Hold Thesis

MASON, Ohio--( BUSINESS WIRE )--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.

AtriCure to Participate in the 41st Annual J.P. Morgan Healthcare Conference

MASON, Ohio--( BUSINESS WIRE )-- AtriCure Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that it has been named a winner of the 2022 Diversity, Equity & Inclusion Award from the National Association of Corporate Directors (NACD) as the top company in the Small Cap - Public Company category. The award recognizes boards that have improved their governance and created long-term value for stakeholders by implementing forward-thinking diversity, equity, and inclusion (DE&I) practices.

AtriCure Wins 2022 NACD Diversity, Equity, & Inclusion Award

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will present at the 34th Annual Piper Sandler Healthcare Conference.

AtriCure to Present at 34th Annual Piper Sandler Healthcare Conference

AtriCure, Inc. (NASDAQ:ATRC ) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Robert Marcus - JPMorgan Rick Wise - Stifel Marie Thibault - BTIG John Young - Canaccord Genuity Matthew O'Brien - Piper Sandler Michael Matson - Needham & Company Suraj Kalia - Oppenheimer Operator Good afternoon, and welcome to AtriCure's Q3 2022 Earnings Conference Call. My name is Stacy, and I'll be your coordinator for the call today.

AtriCure, Inc. (ATRC) Q3 2022 Earnings Call Transcript

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2022 financial results.

AtriCure Reports Third Quarter 2022 Financial Results

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in upcoming investor conferences.

AtriCure to Participate in Upcoming Investor Conferences

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2022 financial results on Tuesday, November 1, 2022. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, November 1, 2022, to discuss its third quarter 2022 financial results. To access the webcas

AtriCure to Announce Third Quarter 2022 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will host an investor education webcast at 2:00 p.m. Eastern Time on Wednesday, September 28, 2022, focusing on Hybrid AF Therapy. The webcast will include remarks from management and key opinion leaders, as well as an interactive question and answer ses

AtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference. AtriCure's management is scheduled to present on Tuesday, September 13, 2022, at 1:30 p.m. Eastern Time. Interested parties may access a live audio webcast of

AtriCure to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

AtriCure, Inc. (NASDAQ:ATRC ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Marissa Bych - Investor Relations Mike Carrel - President and Chief Executive Officer Angie Wirick - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan John McAulay - Stifel Marie Thibault - BTIG William Plovanic - Canaccord David Saxon - Needham Suraj Kalia - Oppenheimer Matthew O'Brien - PSC Operator Good afternoon and welcome to the AtriCure Second Quarter 2022 Earnings Conference Call. My name is Michelle and I will be your coordinator for today's call.

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q2 2022 Results - Earnings Call Transcript

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2022 financial results. “We delivered a remarkable second quarter as we continue changing the standard of care for millions of patients globally,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “Our results demonstrate

AtriCure Reports Second Quarter 2022 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2022 financial results on Tuesday, August 2, 2022. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, August 2, 2022, to discuss its second quarter 2022 financial results. To access the webcast,

AtriCure to Announce Second Quarter 2022 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the first patient was treated in the HEAL-IST™ trial (NCT 05280093). The first patient was treated by Drs. Mark LaMeir and Carlo de Asmundis at University Hospital Brussels. The HEAL-IST trial will evaluate the safety and effectiveness of AtriCure's Iso

AtriCure Announces the First Patient Treated in the HEAL-IST Clinical Trial

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief Human Resources Officer, effective today. Ms. Yount will have responsibility for global Human Resources activities. “We are excited to have Deborah joining us at AtriCure,” said Michael Carrel, President and Chief Executiv

AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer

AtriCure Inc. (NASDAQ:ATRC ) Q1 2022 Results Conference Call May 3, 2022 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group Michael Carrel - President, CEO Angela Wirick - CFO Conference Call Participants Robbie Marcus - JPMorgan Danielle Antalffy - SVB Leerink John McAulay - Stifel Sam Eiber - BTIG David Saxon - Needham Matthew O'Brien - Piper Sandler Suraj Kalia - Oppenheimer Operator Good afternoon, and welcome to AtriCure's First Quarter 2022 Earnings Conference Call. My name is Jeff and I will be your coordinator for call today.

AtriCure Inc. (ATRC) CEO Michael Carrel on Q1 2022 Results - Earnings Call Transcript

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2022 financial results. “Our team delivered exceptional first quarter performance, with broad-based growth across all key products,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “With EPi-Sense® adoption building, con

AtriCure Reports First Quarter 2022 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that it has launched the EnCompass Clamp®, a part of the Isolator Synergy™ Ablation System in the United States. The EnCompass Clamp received FDA 510(k) clearance for ablation of cardiac tissue during cardiac surgery and is designed to make concomitant surgi

AtriCure Launches EnCompass® Clamp, a part of Isolator Synergy™ Ablation System

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2022 financial results on Tuesday, May 3, 2022. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, May 3, 2022 to discuss its first quarter 2022 financial results. The call may be accessed throu

AtriCure to Announce First Quarter 2022 Financial Results

The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think AtriCure (ATRC) Could Surge 52%: Read This Before Placing a Bet

AtriCure Inc. (ATRC) CEO Michael Carrel on Q4 2021 Results - Earnings Call Transcript

MASON, Ohio,--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2021 and full year 2021 financial results. “We achieved several milestones in 2021 including the approval and launch of Hybrid Therapy™ for treatment of patients with long-standing persistent Afib, a result of our groundbreaking CONVERGE™ tri

News for AtriCure Stock (ATRC)